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Abstract
Background: Adenocarcinoma of the small bowel is a relatively rare malignancy as compared to
the other malignancies of the gastrointestinal tract. Nonspecific presentation and infrequent
occurrence often leads to a delay in diagnosis and consequent poor prognosis. Various other
factors are of prognostic importance while managing these tumors.
Methods: The medical records of a total of 27 patients treated for adenocarcinoma of the small
bowel at Providence Hospital and Medical Centers from year 1990 through 2003 were reviewed
retrospectively. Data were analyzed using SPSS software (version 10.0; SPSS, Inc., Chicago, IL).
Survival analyses were calculated using the Kaplan Meier method with the log rank test to assess
the statistical significance. The socio-demographics (age, gender) were calculated using frequency
analyses.
Results: The patients included nine males and eighteen females with a median age at diagnosis of
62 years. Only 48% of the patients had an accurate preoperative diagnosis while another 33% had
a diagnosis suspicious of small bowel malignancy. None of the patients presented in stage 1. The
cumulative five-year survival was 30% while the median survival was 3.3 years. There was no 30-
day mortality in the postoperative period in our series.
Conclusion: The univariate analysis demonstrated that tumor grade, stage at presentation, lymph
nodal metastasis and resection margins were significant predictors of survival.
Background
Although the small bowel represents 90% of the surface
area and 75% of the length of the alimentary tract and is
located between two organs with high cancer incidence
(i.e., stomach and colon), malignant neoplasm of the
small bowel fall in the category of rare neoplasms. They
account for only 2% of all GI malignancies. Even though,
the first collective series of malignant small bowel neo-
plasm was published by Leichtenstein [1] in 1876, small
bowel neoplasms continue to present a challenge to the
clinician due to their infrequency, nonspecific symptoms
and a delay in diagnosis. While the projected incidence in
the United States is 22,280 cases of gastric cancer and
148,610 cases of colorectal cancer for the year 2006, the
similar figure for small bowel cancer is only about 6,170
cases [2]. The prognosis of primary small bowel cancer
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remains dismal with 5-year survival rates ranging from
20% to 30%. This is a retrospective study aimed to report
our experience with diagnosis and management of aden-
ocarcinoma of the small bowel over the last decade in an
effort to determine the factors influencing the long-term
survival. The median follow up of patients was 7.9 years
ranging from 0.6 to 13 years.
Patients and Methods
This study includes a total of 27 patients who were diag-
nosed with adenocarcinoma of the small bowel at Provi-
dence Hospital between 1990 and 2003. The primary
tumor was located between the duodenum and the ileum.
However, periampullary cancers and patients with com-
peting malignancies were excluded from this analysis.
Data on demographics, presenting symptoms, diagnostic
methods, surgical procedures, histopathology and the
outcome of the patients were abstracted retrospectively
from the medical records and tumor registry. The follow-
up ranged from 0.6 to 13 years, median follow up being 7
years. The TNM categories and the extent of residual
tumor after resection were classified according to the
UICC 1997 criteria. Data were analyzed using SPSS soft-
ware (version 10.0; SPSS, Inc., Chicago, IL). Survival anal-
yses were calculated using the Kaplan Meier method with
the log rank test to assess the statistical significance. The
socio-demographics (age, gender) were calculated using
frequency analyses. A p-value of < 0.05 was used to indi-
cate statistical significance.
Results
Age/sex/symptoms
Of the 27 patients, nine were male and 18 were female.
The median age at the time of diagnosis was 62 years. The
majority (62.9%) of the patients were between 61–70
years of age and 35% were between 50–60 years old. The
initial symptoms and physical signs are shown in Table 1.
The diagnostic methods used are shown in Table 2. Thir-
teen of 27 patients (48%) were operated on with a proven
diagnosis, an additional nine patients (33%) had a diag-
nostic suspicion of a small bowel tumor, and five patients
(19%) had an unclear preoperative diagnosis. Interest-
ingly, all the patients with duodenal adenocarcinoma (13
out of 27 patients) had a confirmed preoperative diagno-
sis. For the jejunal and ileal adenocarcinomas, the uncer-
tainty in preoperative diagnosis was encountered
irrespective of the duration of the symptoms, the location
of the tumor within the small bowel or the diagnostic pro-
cedures used. The mean time to establish diagnosis is 14
days. None of the patients in our study had a known diag-
nosis of either celiac disease or Crohn's disease.
Location of tumor/operative procedures/morbidity/
mortality
The tumor was located in the duodenum in 48% of the
patients while 22% had a lesion in the jejunum and 30%
had a lesion in the ileum. Elective surgery was performed
in 89% and emergency surgery in 11% of the patients. The
operative procedures performed are listed in Table 3.
Two patients with jejunoileal tumors undergoing emer-
gency procedures were found to have superficial liver nod-
ules, and one patient with similar pathology undergoing
elective procedure was found to have superficial liver nod-
ules and a distal pancreatic mass. The liver nodules and
distal pancreatic mass in the latter patient were resected in
the same sitting. For the duodenal adenocarcinomas asso-
ciated with liver metastases, surgical bypass was all that
was performed to palliate the obstructive symptoms. For
all jejunoileal resectable tumors, systemic lymph node
dissection was carried out which entailed a resection
extending into the base of mesentery of the diseased seg-
ment of the small bowel.
Table 3: Operative procedures
Operative Procedure N (%)
Palliative bypass 3 (15%)
Pancreaticodoudenectomy 8 (30%)
Segmental resection with primary anastomosis 7 (26%)
En bloc resection 9 (33%)
Table 1: Initial symptoms of the patients
N (%)
Nausea/vomiting 20 (74%)
Abdominal pain 17 (63%)
Melena 13 (48%)
Weight loss 10 (37%)
Anemia 9 (33%)
Palpable abdominal mass 9 (33%)
Dyspepsia complaints 9 (33%)
Intestinal obstruction 6 (22%)
Jaundice 4 (15%)
Table 2: Diagnostic methods applied to the patients
N (%)
Abdominal ultrasonography 25 (93%)
Laparotomy 14 (52%)
Abdominal computed tomography 27 (100%)
Contrast radiography of small bowel 11 (40%)
Contrast radiography of stomach and duodenum 2 (7%)
Gastroduodenoscopy 13 (48%)
Mesenteric Angiography 5 (18%)
Tagged-RBC scan 4 (15%)World Journal of Surgical Oncology 2008, 6:12 http://www.wjso.com/content/6/1/12
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Overall eight patients (30%) had postoperative complica-
tions: three wound infections (two in duodenal tumors
and one in jejunal tumor), three pancreatic fistulas, one
case of pneumonia (duodenal tumor), and one anasta-
motic leakage (duodenal tumor). All three patients with
pancreatic fistulas were managed successfully with con-
servative management only and did not require surgical
intervention. The complications encountered are depicted
in Table 4. No 30-day mortality in this series was noted.
Survival statistics
The median survival of the patients included in this study
was 39 months (Figure 1). The overall five-year survival
was 30%. Using Kaplan-Meier statistics, there was no
detected influence of age and gender on the survival of the
patients. However, several other prognostic factors were
found influencing the survival of these patients. The
median survival was 66 months for patients with well-dif-
ferentiated tumors; 40 months with moderately differen-
tiated tumors and 14 months with poor differentiation.
These differences were statistically significant (p <
0.0001). The existence of distant metastasis was also
found to be significant predictor of survival, (p < 0.0001).
Nodal negative patients were found to have a median sur-
vival of 78 months, whereas, nodal positive patients had
a median survival of 26 months. This difference in sur-
vival was found to be statistically significant (p < 0.0001,
Figure 2).
The difference in survival of patients with resected jeju-
noileal adenocarcinomas (including radical en bloc resec-
tion and metastasectomy) and those with
pancreaticoduodenectomy for duodenal adenocarcino-
mas was not statistically significant even though there was
a trend towards better survival for patients undergoing
enbloc resection for jejunoileal tumors (p = 0.59, Figure
3). However, median survival of patients with unresecta-
ble tumor was only 10 months, and the difference was sta-
tistically significant from those with a resectable tumor (p
< 0.0001, Figure 3). The difference in survival of patients
undergoing radical en bloc resection for jejunoileal tumors
as compared to those undergoing pancreaticoduodenec-
tomy was, however, not statistically significant.
In the current study, two patients with resected duodenal
tumors had a positive microscopic margin (R1) on perma-
nent section, and three patients with jejunoileal tumors
had gross residual tumor after undergoing metastectomy
(R2). Median survival was 14 months for those with a
residual tumor (R1 and R2 positive margin), and 42
months for those with R0 or negative margin (p < 0.0001,
Figure 4).
Another significant prognostic factor of survival was the
stage of tumor at the time of diagnosis. Patients with stage
IV tumors had a median survival of ten months, those
with stage 3 tumors had a median survival of 36 months
and those with stage II tumors had a median survival of 78
months (p < 0.0001, Figure 5). None of the patients had
a stage I tumor at diagnosis. Vascular invasion also
showed a significant difference in survival (p < 0.0001,
Figure 6). Patients with vascular invasion had a median
survival of 15 months and those without vascular inva-
sion had a median survival of 61 months. Even though
the survival of patients with tumor located in the duode-
Survival by Lymph Node Involvement Figure 2
Survival by Lymph Node Involvement.
Table 4: Complications
Complication N (%)
Wound infection 3(11%)
Pancreatic fistula 3(11%)
Pneumonia 1(4%)
Anastamotic leak 1(4%)
Overall Survival Figure 1
Overall Survival.World Journal of Surgical Oncology 2008, 6:12 http://www.wjso.com/content/6/1/12
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num tended to be lower than that for tumors located dis-
tally, the location of tumor within the small bowel was
not found to be a statistically significant prognostic factor.
Five patients with stage III adenocarcinoma and four
patients with stage IV adenocarcinoma received chemo-
therapy. The results of this study showed no significant
difference between the survival rates of patients who
received chemotherapy as compared to those who did
not.
Discussion
Primary malignant tumors of the small bowel are rare.
These are mainly adenocarcinomas followed in decreas-
ing order by carcinoid tumors, non-Hodgkin lymphomas,
gastrointestinal stromal tumors, melanomas, and other
rare entities. In the United States, the incidence of all types
of small bowel cancer is estimated to be approximately
5,300 cases per year and approximately 1,100 patients die
from small bowel cancer each year. The development of
an adenocarcinoma of the small bowel has been related to
the mucosal contact time with bile acid solutions. Ross et
al. [3] showed that the frequency of tumor distribution
within the small bowel correlates with the length of
mucosal contact with pancreatico-biliary secretions,
implicating bile as a possible carcinogen. This is sup-
ported by findings that the active and passive transport of
bile acid solutions is limited to the ileum [4].
In concordance with other reports, adenocarcinomas
located in the small bowel, as other malignant entities of
the small bowel, are observed mainly between 50 and 70
years of age [5-14]. In general, an accurate preoperative
diagnosis has been reported only in 30%–72% of cases
[10,11,15-24]. The clinical signs and symptoms may vary
Survival by Vascular Involvement* Figure 6
Survival by Vascular Involvement*. One out of 27 
patients did not have data on vascular invasion in the his-
topathological report.
Survival by Margin Involvement* Figure 4
Survival by Margin Involvement*. 3 patients had unre-
sectable tumors, and, therefore, have been excluded from 
this analysis.
Survival by Resection Procedure Figure 3
Survival by Resection Procedure.
Survival by Stage Figure 5
Survival by Stage.World Journal of Surgical Oncology 2008, 6:12 http://www.wjso.com/content/6/1/12
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with the tumor site, size, and existence of ulceration. The
common presenting signs and symptoms in our series
were nausea, vomiting, abdominal pain, melena, weight
loss, anemia, and a palpable mass, none of which was
pathognomonic for small bowel tumors. All duodenal
adenocarcinomas were diagnosed preoperatively by a gas-
tro-duodenoscopy. For tumors in the jejunum and ileum,
computer tomography and small bowel contrast study
provided clues suggestive of small bowel tumor. Upper
gastrointestinal tract series with small intestinal follow
through is one of the most useful diagnostic tests. It yields
an accurate diagnosis in 50 to 70% of patients with the
neoplasm of small intestine [23]. Localization of intermit-
tent-bleeding small bowel tumors through angiography
and tagged-red blood cell radioisotope scan was also help-
ful in our study. Depending on the clinical symptoms, an
emergency operation may be necessary. Seven patients
(26%) in this study received emergency surgical treat-
ment. Three of them had gastrointestinal hemorrhage and
five had intestinal obstruction. Of importance is the fact
that all the tumors requiring emergency surgery were
located in the jejunum or the ileum. Thus, an accurate
pathologic diagnosis could be achieved intraoperatively
in these cases. The rate of diagnosis of small bowel tumors
of all types by laparotomy varies between 40 and 80% in
the literature [25]. In our study, the rate of diagnosis dur-
ing laparotomy for small bowel adenocarcinoma was
52%. As known from the literature [14,24], adenocarcino-
mas are predominant in the duodenum. The more distal
tumors were found more frequently in the jejunum than
the ileum, which, however, is not a case in our study (30%
in the ileum, and 22% in the jejunum). Brucher et al.,
found no patient with adenocarcinoma of the ileum in
their series [14]. Recently, Dabaja et al., reported a 13%
incidence of adenocarcinoma in the ileum [24].
In 1990 Sellener described an adenoma-adenocarcinoma-
sequence [26] and In 1992 Lashner reported Crohn's dis-
ease as a risk factor in developing adenocarcinomas in the
small bowel [27]. Rodriguez-Bigas et al [28], found an
association between hereditary nonpolyposis colorectal
carcinoma (HNPCC) patients and the increased risk of
small bowel adenocarcinoma. In a review by Groves et al.
[29], a total of six out of 114 patients of familial adenom-
atous polyposis (FAP) developed duodenal adenocarci-
noma over a follow-up period of ten years. None of the
patients in our study were known to have FAP, Crohn's
disease or HNPCC.
The type of surgery varied according to the operating sur-
geons. For duodenal adenocarcinomas, 62% (eight out of
13 patients) of patients underwent pancreaticoduodenec-
tomy and 15% (two out of 13 patients) underwent seg-
mental duodenal resections with curative intent. Palliative
bypass procedures were performed for the remaining
patients with metastatic adenocarcinomas of the duode-
num. For adenocarcinomas of the jejunum and ileum,
Nine out of 14 patients underwent en bloc radical resec-
tion, which included three patients with metastectomy,
and five out of 14 patients with localized diseases under-
went segmental resections. When performing analysis, the
palliative procedures had the shortest median survival (10
months) when compared to pancreaticoduodenectomies
(34 months) and radical resections of the jejunoileal dis-
eases (40 months). The demand of a higher technical
expertise for resection of duodenal tumors as compared to
resectable jejunoileal tumors may explain the inferior sur-
vival of patients with duodenal tumors, as demonstrated
by the fact that significant morbidity in our series occurred
only in patients with the tumor located in the duodenum.
Importantly, every effort should be done to obtain R0
resection when dealing with small bowel adenocarci-
noma because of a significant survival advantage.
Howe et al., [5] reviewed 4,995 patients with small bowel
adenocarcinoma from the National Cancer Data Base
from 1985–1995 and found the following factors to cor-
relate with survival: patient age, tumor site (favoring jeju-
num and ileum), clinical staging, and whether curative
resection was performed. Bakaeen et al. [6] and Ryder et al.
[7] found tumor size, histologic grade, nodal metastases,
and positive surgical margin to be prognostic factors pre-
dicting survival of adenocarcinomas of the duodenum.
Brucher et al. [14] identified the presence of the residual
tumor, tumor stage, lymph node metastasis, distant
metastasis, lymphangiosis carcinomatosa, and vascular
invasion as prognostic factors. Dabala et al. [24] recently
reported that only cancer-directed surgery and lymph
node involvement ratio to be independent predictors of
overall survival in a multivariate analysis.
In our current study, the five-year survival was 30%, which
is similar to that reported in pat literature [18]. We also
found the presence of a positive node (p < 0. 0001), vas-
cular invasion (p < 0.0001), and poor cellular differentia-
tion (p < 0.0001) to be prognostic indicators, which is
also analogous to the report of Brucher et al [14].
Conclusion
A complete tumor resection has to be the aim of any cur-
ative surgical approach in patients with adenocarcinoma
of the small bowel. The first step in improving the prog-
nosis is to have an aggressive diagnostic approach in
patients with unclear abdominal symptoms. The delay of
diagnosis is responsible for the presentation of these
patients at advanced tumor stages. Based on our data, the
standard of the oncological surgery should be a systemic
lymph node dissection and a radical enbloc R0 resection.
Moreover, further investigation into the fundamental
mechanisms driving the initiation and progression ofPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
World Journal of Surgical Oncology 2008, 6:12 http://www.wjso.com/content/6/1/12
Page 6 of 6
(page number not for citation purposes)
small bowel cancers is needed. Although such investiga-
tions are considered to be low priority, given the low inci-
dence of this cancer, findings in these studies may have
important implications for more prevalent cancers.
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